Effect of hormonal contraception on the course of lupus nephropathy

Influence of oral contraceptive therapy on SLE activity was evaluated in 33 female patients with lupus nephropathy. Estroprogestative preparations containing either 50 micrograms (18 cases) or 30 micrograms (11 cases) of ethinylestradiol were used in 29 courses in 28 patients. Onset or exacerbation...

Full description

Saved in:
Bibliographic Details
Published inLa Nouvelle presse medicale Vol. 11; no. 51; p. 3765
Main Authors Jungers, P, Dougados, M, Pélissier, C, Kuttenn, F, Tron, F, Pertuiset, N, Bach, J F
Format Journal Article
LanguageFrench
Published France 18.12.1982
Subjects
Contraceptives, Oral - adverse effects
Contraceptives, Oral, Hormonal - adverse effects
Ethinyl Estradiol - adverse effects
Female
Humans
Kidney Diseases - etiology
Kidney Diseases - physiopathology
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - physiopathology
Progesterone Congeners - adverse effects
Time Factors
Systemic Lupus Erythematosus
Hemic System
Contraceptive Agents
Oral Contraceptives > side effects
Reproductive Control Agents
Biology
Contraception
Contraceptive Methods > side effects
Family Planning
Diseases
Hematological Effects
Physiology
Contraceptive Agents, Female
Online AccessGet more information

Cover

More Information
Summary:Influence of oral contraceptive therapy on SLE activity was evaluated in 33 female patients with lupus nephropathy. Estroprogestative preparations containing either 50 micrograms (18 cases) or 30 micrograms (11 cases) of ethinylestradiol were used in 29 courses in 28 patients. Onset or exacerbation of clinical SLE activity occurred within 3 months after starting hormonal therapy in 13 cases, an overall incidence of lupus flare-up of 44 percent, involving major renal histological lesions in 5 cases. In contrast, of 16 patients receiving pure progestogen contraceptive therapy with either discontinuous normal dosage progestogens (9 cases) or continuous low-dose norsteroids (7 cases), only one developed clinical or immunological evidence of lupus exacerbation within 3 months of hormonal therapy. We conclude that oral contraceptive therapy using estrogens, even at low dosage, is associated with a high risk of SLE exacerbation. Pure progestogens, which have proven effective and devoid of such unfavorable effects, should be preferred in these patients when hormonal contraception is needed.
ISSN:0301-1518